OncoMatch/Clinical Trials/NCT06405230
Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Organoid (PDOs)s and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC)
Is NCT06405230 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including Pembrolizumab and Dostarlimab for lung cancer, non-small cell.
Treatment: Pembrolizumab · Dostarlimab · Pemetrexed+ (carboplatin or cisplatin) — The goal of this clinical trial is to investigate the utility of biomarker tools Extracellular Vesicles (EVs), Patient-derived organoid (PDOs), and PDL1 PET imaging for predicting how participants with recurrent NSCLC respond to standard of care treatment in the advanced/metastatic stages.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: PD-L1 (CD274) identifiable PDL1 status
Identifiable PDL1 status prior to randomisation
Excluded: EGFR sensitizing mutation
NSCLC with known sensitizing EGFR mutations ... from resected tissue at the time of initially surgery and/or tissue biopsy at the time of screening
Excluded: ALK translocation
NSCLC with known ... Anaplastic lymphoma kinase (ALK) translocations ... from resected tissue at the time of initially surgery and/or tissue biopsy at the time of screening
Excluded: ROS1 mutation
NSCLC with known ... c-ros oncogene 1 (ROS1) mutations from resected tissue at the time of initially surgery and/or tissue biopsy at the time of screening
Disease stage
Required: Stage I, II, III
Metastatic disease required
Participants must have biopsy-confirmed recurrence of their initial NSCLC with advanced/metastatic presentation
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: surgery — curative resection ± (neo) adjuvant treatment
Participants must have been initially diagnosed with operable Stage 1-3 NSCLC and received curative resection ± (neo) adjuvant treatment
Cannot have received: anti-PD-(L)1 therapy
Exception: allowed if last dose ≥6 months before first 89Zr-durvalumab-PET tracer injection
For participants who received adjuvant therapy that included anti-PD(L)1 Checkpoint inhibitor (CPI) following surgical resection, their last dose of anti-PD(L)1 was <6 months from the date of first 89Zr-durvalumab-PET tracer injection
Cannot have received: any anti-cancer therapy for lung cancer recurrence after initial surgery
Participant has received any form of anti-cancer therapy (e.g., chemotherapy, radiation, immunotherapy) for lung cancer recurrence after initial surgery
Cannot have received: additional anticancer post-surgery±(neo) adjuvant therapy or experimental therapy
Is receiving any additional anticancer post-surgery±(neo) adjuvant therapy or experimental therapy. No other experimental therapies ... are permitted while the participant is receiving study intervention
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify